A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-301 Clinical Trial

NCT ID: NCT04590703

Last Updated: 2023-08-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

73 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-06-24

Study Completion Date

2023-06-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a follow-up study to evaluate the safety for the subjects with ALLO-ASC-DFU treatment in phase 3 clinical trial (ALLO-ASC-DFU-301) for 24 months

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an open-label follow up study to evaluate the safety for the subjects with ALLO-ASC-DFU treatment in phase 3 clinical trial (ALLO-ASC-DFU-301) for 24 months. ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a Diabetic Foot Ulcer.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Foot Ulcer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ALLO-ASC-DFU

Subjects with ALLO-ASC-DFU treatment in phase 3 clinical trial of ALLO-ASC-DFU-301

ALLO-ASC-DFU

Intervention Type BIOLOGICAL

Application of ALLO-ASC-DFU sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.

Vehicle sheet

Subjects with Vehicle sheet treatment in phase 3 clinical trial of ALLO-ASC-DFU-301

Vehicle sheet

Intervention Type PROCEDURE

Application of Vehicle sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ALLO-ASC-DFU

Application of ALLO-ASC-DFU sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.

Intervention Type BIOLOGICAL

Vehicle sheet

Application of Vehicle sheet to Diabetic Foot Ulcer. This study is a follow-up study without intervention.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects who are treated with ALLO-ASC-DFU sheet or Vehicle sheet in phase 3 clinical trial of ALLO-ASC-DFU-301.
2. Subjects who are able to give written informed consent prior to study start and to comply with the study requirements.

Exclusion Criteria

1\. Subjects who are considered not suitable for the study by the principal investigator.
Minimum Eligible Age

19 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Anterogen Co., Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

SeungKyu Han, MD. Ph D.

Role: PRINCIPAL_INVESTIGATOR

Korea University Guro Hospital

KiWon Young, MD. Ph D.

Role: PRINCIPAL_INVESTIGATOR

Nowon Eulji Medical Center, Eulji University

JunPyo Hong, MD. Ph D.

Role: PRINCIPAL_INVESTIGATOR

Asan Medical Center

JunHyeong Kim, MD. Ph D.

Role: PRINCIPAL_INVESTIGATOR

Keimyung University Dongsan Medical Center

Chan Kang, MD. Ph D.

Role: PRINCIPAL_INVESTIGATOR

Chungnam National University Hospital

HyungMin Hahn, MD. Ph D.

Role: PRINCIPAL_INVESTIGATOR

Ajou University Medical Center

ChanYeong Heo, MD. Ph D.

Role: PRINCIPAL_INVESTIGATOR

Seoul National University Bundang Hospital

YoungKoo Lee, MD. Ph D.

Role: PRINCIPAL_INVESTIGATOR

Soonchunhyang University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chungnam National University Hospital

Daejeon, Chungcheongnam-do, South Korea

Site Status

Soonchunhyang University Hospital

Bucheon-si, Gyeonggi-do, South Korea

Site Status

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, South Korea

Site Status

Ajou University Medical Center

Suwon, Gyeonggi-do, South Korea

Site Status

Keimyung University Dongsan Medical Center

Daegu, Gyeongsangnam-do, South Korea

Site Status

Nowon Eulji Medical Center, Eulji University

Seoul, , South Korea

Site Status

Asan Medical Center

Seoul, , South Korea

Site Status

Korea University Guro Hospital

Seoul, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ALLO-ASC-DFU-303

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

NK Cell Therapy Recurrent/Refractory Elderly AML
NCT04599452 UNKNOWN PHASE1/PHASE2